Drugs / GH2616
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07260513 | Mar 2025 → Dec 2028 expected | — | Suzhou Genhouse Bio Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-16 | Suzhou Genhouse Bio Co., Ltd. | Results 勤浩医药宣布在2023年美国癌症研究协会（AACR）年会公布两项临床前研究数据 genhousebio.com ↗
在动物实验中，GH2616对于WGD肿瘤细胞的CDX模型展现出剂量依赖的药效。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-16 | Suzhou Genhouse Bio Co., Ltd. | 勤浩医药宣布在2023年美国癌症研究协会（AACR）年会公布两项临床前研究数据 genhousebio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GH2616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260513 ↗ |
| Action | Inhibit | “inhibiting KIF18A activity” NCT07260513 ↗ |
| Route | Oral | “Subjects will receive GH2616 orally” NCT07260513 ↗ |
| Target | KIF18A | “GH2616 is a potent and selective inhibitor targeting KIF18A” NCT07260513 ↗ |